The Cochrane review confirms the statistically significant efficacy of low-level laser for chronic low back pain, with a better safety profile than medications.
This Cochrane systematic review (DOI 10.1002/14651858.CD009923, updated 2022) constitutes the most rigorous international reference on the efficacy of low-level laser therapy (LLLT) for nonspecific acute and chronic low back pain.
Cochrane reviews represent the gold standard of medical evidence synthesis: they apply a strict methodology for study inclusion, bias assessment and meta-analysis to produce reliable conclusions on the efficacy of interventions.
The authors analyzed 30 randomized scientific trials (more than 1,800 participants) comparing LLLT to placebo (sham laser), to active treatments (physiotherapy, NSAIDs) or to therapeutic combinations for different types of low back pain.
RCTs with sham-control (inactive placebo laser blinded to the patient). Adult patients with acute (<6 weeks), subacute (6–12 weeks) or chronic (>12 weeks) low back pain. Assessment by independent researchers.
Wavelengths 632–1,064 nm. Power densities of 5 to 100 mW/cm². Doses of 0.1 to 12 J/cm². Number of sessions: 5 to 20. Protocol durations: 2 to 8 weeks. Pulsed and continuous application modes.
Pain intensity (VAS 0-100, NRS 0-10). Functional disability (Oswestry Disability Index, Roland-Morris). Quality of life (SF-36). Return to work. Patient satisfaction. Reported side effects.
Cochrane RoB 2.0 tool: randomization, allocation concealment, participant/assessor blinding, missing data, selective outcomes. GRADE quality for each result. Meta-analysis using random effects model.
Chronic low back pain is the leading cause of disability worldwide and one of the most costly conditions for healthcare systems. This Cochrane review provides a decisive answer on the scientific utility of laser therapy as an alternative or complement to drug treatments.
What fundamentally distinguishes LLLT from NSAIDs and opioids, the conventional treatments for low back pain, is the complete absence of systemic side effects. No gastrointestinal risk, no dependence, no drug interaction. For our patients on anticoagulant treatment or with a history of ulcers, this characteristic is decisive.
In our practice, we systematically combine LLLT with a targeted muscle-strengthening protocol, which potentiates the effects of each modality: laser reduces pain enough to allow active rehabilitation, which in turn addresses the structural cause of low back pain.
The persistence of effects at 3 months without additional treatment suggests an actual tissue regeneration mechanism, rather than simple pain masking. Our patients report a progressive improvement that consolidates over time.